EP300 and neoplasm: At the same time, in silico analyses of retrospective data for various solid tumors have shown that mutations in CREBBP and EP300 are associated with immune-inflamed tumors characterized by high neoantigen load, high PD-L1 expression, and a tumor microenvironment rich in T and NK cells, identifying them as potential biomarkers for immunotherapy [21,32,77].